Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et åbent studie til evaluering af PF-07994525 hos deltagere med fremskredne kræftformer

3. november 2026 opdateret af: Pfizer

Et åbent mærket Fase 1-studie til vurdering af PF-07994525 hos deltagere med fremskredne maligniteter

This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.

The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.

Studieoversigt

Status

Rekruttering

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

120

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Rekruttering
        • Arthur J.E. Child Comprehensive Cancer Centre
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Ikke rekrutterer endnu
        • Juravinski Cancer Centre
      • Toronto, Ontario, Canada, M5G2M9
        • Rekruttering
        • University Health Network- Princess Margaret Cancer Centre
    • Colorado
      • Denver, Colorado, Forenede Stater, 80218
        • Rekruttering
        • Colorado Blood Cancer Institute
      • Denver, Colorado, Forenede Stater, 80218
        • Rekruttering
        • Presbyterian/St. Luke's Medical Center
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06511
        • Rekruttering
        • Smilow Cancer Hospital Phase 1 Unit
      • New Haven, Connecticut, Forenede Stater, 06510
        • Rekruttering
        • Yale-New Haven Hospital-Yale Cancer Center
      • New Haven, Connecticut, Forenede Stater, 06510
        • Rekruttering
        • Smilow Cancer Hospital - Yale New Haven Health
      • New Haven, Connecticut, Forenede Stater, 06511
        • Rekruttering
        • Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
      • North Haven, Connecticut, Forenede Stater, 06473
        • Rekruttering
        • Smilow Cancer Hospital - North Haven
    • Florida
      • Coral Gables, Florida, Forenede Stater, 33146
        • Rekruttering
        • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
      • Coral Springs, Florida, Forenede Stater, 33065
        • Rekruttering
        • Sylvester Comprehensive Cancer Center - Coral Springs
      • Deerfield Beach, Florida, Forenede Stater, 33442
        • Rekruttering
        • University of Miami Hospital and Clinics - Deerfield Beach
      • Doral, Florida, Forenede Stater, 33166
        • Rekruttering
        • Sylvester Comprehensive Cancer Center- Doral
      • Hollywood, Florida, Forenede Stater, 33021
        • Rekruttering
        • Sylvester Comprehensive Cancer Center - Hollywood
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • Sylvester Comprehensive Cancer Center
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • University of Miami Hospital and Clinics
      • Miami, Florida, Forenede Stater, 33176
        • Rekruttering
        • Sylvester Comprehensive Cancer Center- Kendall
      • North Miami, Florida, Forenede Stater, 33181
        • Rekruttering
        • Sylvester Comprehensive Cancer Center - Sole Mia
      • Plantation, Florida, Forenede Stater, 33324
        • Rekruttering
        • Sylvester Comprehensive Cancer Center - Plantation
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30308
        • Rekruttering
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Hospital
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Winship Cancer Institute, Emory University
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • The James Cancer Hospital and Solove Research Institute
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • Ohio State University Hospitals
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • The James Outpatient Care West Campus
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Sarah Cannon Research Institute - Pharmacy
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Tristar BMT
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • SCRI Oncology Partners
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • TriStar Centennial Medical center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
  • Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)

Measurable disease based on IMWG criteria as defined by at least 1 of the following:

  1. Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)

  2. Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)

  3. Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)

    • Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
    • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Exclusion Criteria:

  • Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
  • Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
  • Active or suspected cerebral/meningeal disease related to the underlying malignancy.
  • Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part 1

Monotherapy Dose Expansion

Oral administration

Oral administration

Eksperimentel: Part 2

Monotherapy Dose Escalation

Oral administration

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Type, incidence and severity of participants with adverse events (AEs)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs)

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Type, incidence and severity of participants with laboratory abnormalities
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Number of participants with dose modifications
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Tidsramme: Baseline to end of DLT evaluation period

Occurrence of DLTs as defined by the protocol

Baseline to end of DLT evaluation period
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Part 2: Recommended Dose for future development
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Safety, and preliminary anti-tumor activity

From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objektiv responsrate (ORR) ifølge International Myeloma Working Group (IMWG) responskriterier som fastsat af undersøgeren.
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikræftbehandling (cirka 2 år)
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikræftbehandling (cirka 2 år)
Komplet responsrate (CRR) ifølge International Myeloma Working Group (IMWG) responskriterier som bestemt af undersøgeren.
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikræftbehandling (cirka 2 år)
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikræftbehandling (cirka 2 år)
Tid til respons (TTR) ifølge IMWG som bestemt af undersøgeren
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikancerbehandling (ca. 2 år)
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikancerbehandling (ca. 2 år)
Varigheden af respons (DOR) pr. IMWG som fastlagt af undersøgeren
Tidsramme: Fra baseline til datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (cirka 2 år)
Fra baseline til datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (cirka 2 år)
Varighed af komplet respons (DOCR) pr. IMWG som bestemt af undersøger
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (cirka 2 år)
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (cirka 2 år)
Progression-fri overlevelse (PFS) pr. IMWG som fastsat af undersøgeren
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (ca. 2 år)
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (ca. 2 år)
Samlet overlevelse (OS)
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (ca. 2 år)
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (ca. 2 år)
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: Cmin as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: Accumulation ratio (Rac) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Pharmacokinetic (PK) assessments for PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
AUC from time zero to time of last measurable concentration (AUClast)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Time to Maximum concentration (Tmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Maximum Observed Concentration (Cmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525

From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juli 2026

Primær færdiggørelse (Anslået)

10. juli 2029

Studieafslutning (Anslået)

10. juli 2030

Datoer for studieregistrering

Først indsendt

16. februar 2026

Først indsendt, der opfyldte QC-kriterier

16. februar 2026

Først opslået (Faktiske)

23. februar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • C6331001
  • KAT2i (Anden identifikator: Alias Study Number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner